Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer

2009 ◽  
Vol 66 (2) ◽  
pp. 373-380 ◽  
Author(s):  
Sun Jin Sym ◽  
Min-Hee Ryu ◽  
Hye Jin Kang ◽  
Sung Sook Lee ◽  
Heung-Moon Chang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy ◽  
Phase I Study ◽  
Weekly Docetaxel

A Phase I Study of Weekly Docetaxel, 24-Hour Infusion of High-Dose Fluorouracil/Leucovorin and Cisplatin in Patients with Advanced Gastric Cancer

Oncology ◽  
2002 ◽  
Vol 63 (3) ◽  
pp. 239-247 ◽  
Author(s):  
Li-Tzong Chen ◽  
Tsang-Wu Liu ◽  
Chew-Wun Wu ◽  
Tsai-Rong Chung ◽  
Her-Shyong Shiah ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Phase I Study ◽  
High Dose ◽  
Weekly Docetaxel

scholarly journals A Phase I Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer

2012 ◽  
Vol 43 (2) ◽  
pp. 125-131 ◽  
Author(s):  
Yutaka Kimura ◽  
Hiroshi Yano ◽  
Hiroshi Imamura ◽  
Kazumasa Fujitani ◽  
Motohiro Imano ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy ◽  
Phase I Study

Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer

2012 ◽  
Vol 70 (2) ◽  
pp. 277-284 ◽  
Author(s):  
Sun Jin Sym ◽  
Junsik Hong ◽  
Minkyu Jung ◽  
Jinny Park ◽  
Eun Kyung Cho ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Combination Chemotherapy ◽  
Phase I Study

Phase I study of paclitaxel plus irinotecan combination therapy for patients with refractory and advanced gastric cancer

2006 ◽  
Vol 2 (1) ◽  
pp. 266-271
Author(s):  
T. KOBAYASHI ◽  
T. SAKAGAMI ◽  
H. KOIZUKA ◽  
N. YAMAMOTO ◽  
T. SASAKI ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Combination Therapy ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Phase I Study

A phase I study of S-1 and low dose cisplatin for patients with recurrent or advanced gastric cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4161-4161
Author(s):  
S. Shimoyama ◽  
M. Kaminishi ◽  
N. Hiki ◽  
N. Shimizu ◽  
H. Yamaguchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Phase I Study ◽  
Low Dose

Phase I/II docetaxel, oxaliplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 162-162
Author(s):  
Sung Rok Kim ◽  
Sung-En Park ◽  
Young Jin Yuh ◽  
Byeong Seok Sohn ◽  
Hye Ran Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase I ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Dose Intensity ◽  
Progression Free Survival ◽  
Optimal Dose ◽  
Grade 3 ◽  
Recommended Phase Ii Dose

162 Background: The results of recent studies with duo- or triple regimen for the advanced gastric cancer are still not satisfactory and the optimal doses of combinations with taxanes, fluorouracil and platinum analogues were not determined yet. The aim of this study is to determine the optimal dose of docetaxel and oxaliplatin in combination with 5-fluorouracil(FU) [DOF], with the efficacy and toxicity in patients (pts) with advanced gastric cancer. Methods: The pts with unresectable, metastatic, or relapsed gastric cancer were enrolled for a phase I/II study. The dose of docetaxel and oxliplatin was escalated from 50 mg/m2 and 80 mg/m2 day 1, respectively by traditional 3+3 design, and 5-FU was fixed at 850 mg/m2/day 24 hour continuous infusion day 1-4, all every 3 weeks. All pts had measurable disease and were assessable for toxicity. Results: A total of 50 pts including 12 patients from phase I study were enrolled. The recommended phase II dose of docetaxel and oxaliplatin were 60mg/m2 and 100mg/m2 on day 1 (cohort 2), respectively. A total of 335 cycles of chemotherapy was administrated (median: 6, range 1–24) and the dose intensity of docetaxel, oxaliplatin, and 5-FU were 96.3%, 96.2% and 98.5%, respectively. Twenty two (44.0%) of 50 patients showed partial response, 22 (44.0%) stable disease, and 1 (2.0%) complete response. The overall response rate was 46.0% (95% confidence interval [CI]: 32.2–60.0%) and the disease control rate 90.0% (95% CI: 81.7–98.3%). The median progression free survival was 6.5 months (95% CI, 3.3–9.8) and the overall survival 10.7 month (95% CI, 7.0–14.3). Grade 3/4 neutropenia and thrombocytopenia occurred in 81 (24.1%) and 3 cycles (0.9%), respectively [27 (56%) and 3 (6%) in 50 pts, respectively]. Grade 3/4 stomatitis, diarrhea and neuropathy occurred in 2 (0.6%), 6 (1.8%) and 6 cycles (5.7%), respectively. Conclusions: The recommended phase II dose of docetaxel and oxaliplatin was 60mg/m2 and 100mg/m2, respectively. This DOF combination chemotherapy has no better efficacy than reference regimen. The toxicities were substantial in some pts, but generally manageable.

Sign in / Sign up

Export Citation Format

Share Document